Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dicot Pharma ABOSTO:DICOT -1.86%18 Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus rates OSTO:DICOT with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 678 Drug Manufacturers companies, Dicot Pharma AB ranks better than 99.71% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Dicot Pharma AB's
Operating Income
for the
three
months ended in Jun. 2026 was kr-18.40 Mil. Dicot Pharma AB's Interest Expense for the
three
months ended in Jun. 2026 was kr0.00 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Dicot Pharma AB has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Dicot Pharma AB's Interest Coverage or its related term are showing as below:
OSTO:DICOT'
s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt
OSTO:DICOT's Interest Coverage is ranked better than 99.71% of 678
companies
in the Drug Manufacturers industry
Industry Median: 12.575
vs OSTO:DICOT: No Debt
Dicot Pharma AB (OSTO:DICOT) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Dicot Pharma AB Interest Coverage Related Terms
Dicot Pharma AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for Dicot Pharma AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Dicot Pharma AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dicot Pharma AB Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dicot Pharma AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Dicot Pharma AB's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Dicot Pharma AB (OSTO:DICOT) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Dicot Pharma AB and its competitors. Over the past decade, Dicot Pharma AB's Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Dicot Pharma AB ranks #2 out of 678 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Dicot Pharma AB's Interest Coverage too high?
Dicot Pharma AB's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Dicot Pharma AB ranks #2 out of 678 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dicot Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Dicot Pharma AB's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dicot Pharma AB ranks #2 out of 678 companies for Interest Coverage. This places Dicot Pharma AB in the top 0% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.58. Historically, Dicot Pharma AB's own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.58, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Dicot Pharma AB and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dicot Pharma AB's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dicot Pharma AB stock overvalued right now?
Dicot Pharma AB (OSTO:DICOT) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Dicot Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Dicot Pharma AB (OSTO:DICOT), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation than existing preparations. The business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects, and is also used in the treatment of erectile dysfunction and premature ejaculation.
18GF Score
Get the complete analysis for OSTO:DICOT
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DICOT has been successfully added to your 
